May 3 (Reuters) – Drugmaker Mylan NV posted a 17
percent rise in quarterly revenue, helped by higher generic drug
sales, and stood by its full-year revenue and adjusted profit
guidance.
The post UPDATE 1-Mylan revenue rises on generic drugs boost, reaffirms outlook appeared first on NASDAQ.